Veille documentaire MTPH

J Nucl Med Technol. 2005 Sep;33(3):172-4.
131I in blood samples: a danger for professionals? A problem for immunoassays?
‘Vialard-Miguel J, Georges A, Mazere J, Ducassou D, Corcuff JB.
Nuclear Medicine Department, University Hospital of Bordeaux and University Bordeaux 2, Bordeaux, France. julie.miguel@chu-bordeaux.fr’
OBJECTIVE: Our objective was to investigate the safety of radioactive blood samples from patients receiving 131I and whether the radioactivity affects the validity of assays. METHODS: First, the activity of samples from patients given 131I was measured by 3 methods and compared with the upper threshold. Then, pilot sera were spiked with 131I, and possible interference was investigated using 2 immunoradiometric assays. RESULTS: The activity of 13 of the 15 samples was below the European limit; the other 2 samples were from patients with reduced renal clearance rates. No differences in thyroglobulin level or thyroid-stimulating hormone level were found between sera that were spiked with 131I and sera that were not. CONCLUSION: These blood samples are safe because they contain negligible activity, and the use of radioimmunoassays or immunoradiometric assays on them produces reliable results.
MeSH Terms: Artifacts* – Europe – Health Personnel* – Hematologic Tests – Iodine Radioisotopes/blood* – Iodine Radioisotopes/therapeutic use – Occupational Exposure/analysis* – Radiation Dosage – Radiation Injuries/prevention & control – Radiation Protect